Summary: Avails Medical has initiated a U.S. pilot trial for its electrical AST system, aiming to revolutionize diagnostics by providing same-day antibiotic susceptibility test results directly from positive blood cultures.

Takeaways:

  1. Game-Changing Speed: The eAST system reduces antibiotic susceptibility testing (AST) turnaround from 24-48 hours to same-day results, enabling faster, life-saving treatment decisions.
  2. Combatting Antimicrobial Resistance: By delivering rapid AST results, the system empowers clinicians to address the growing global challenge of antimicrobial resistance effectively.
  3. Real-World Validation: The U.S. pilot trial will evaluate the eAST system’s performance and usability in clinical settings, paving the way for its broader adoption in healthcare.

Avails Medical, a provider in rapid, automated, and fully electrical antibiotic susceptibility testing (eAST), announced the launch of its U.S. pilot trial for the innovative eAST system under development. This milestone highlights the company’s commitment to revolutionizing diagnostics and improving patient care.

Improved Antibiotic Susceptibility Testing

The eAST system, Avails’ flagship multi-slot rapid AST platform is being developed to deliver antibiotic susceptibility test (AST) results directly from positive blood cultures (PBC), enabling potential same-day reporting. By dramatically reducing turnaround times, the system will allow clinicians to make faster, more informed treatment decisions, which can be life-saving for critically ill patients.

“The Avails eAST system is designed to be a groundbreaking low-cost solution and a leap forward in diagnostics,” says Meike Herget, PhD, CTO and co-founder of Avails Medical. “By accelerating AST results, we empower clinicians to save lives and improve outcomes while addressing the growing challenge of antimicrobial resistance.”

Further Reading

FDA Clears New Antibiotic Susceptibility Testing System

Traditional AST methods often take 24 to 48 hours, leaving clinicians waiting for actionable data. The eAST system’s ability to deliver results in hours instead of days could redefine standards in clinical microbiology, offering a scalable and cost-effective solution for healthcare providers.

The U.S. pilot trial will assess the system’s performance and usability in real-world settings.